LY2886721 selectively inhibits the beta-site amyloid protein cleaving enzyme (BACE) (IC50 = 20 nM for recombinant hBACE1). BACE performs the first cleavage step in the Abeta cascade, thus, its inhibition by LY2886721 decreases production of all forms of the Abeta peptide. A Phase II clinical study for the use of...

Description: LY2886721, a BACE inhibitor, is used for the therapy of Alzheimer's Disease. Target: Beta-Secretase, BACE. Smiles: NC1=N[C@]2(COC[C@H]2CS1)c1cc(NC(=O)c2ccc(F)cn2)ccc1F. References: Townsend M, et al. J Alzheimers Dis, 2011, 24 Suppl 2, 43-52.